EOS imaging Obtains FDA Approval for hipEOS, the First 3D Stereoradiographic Planning Software for Hip Arthroplasty

Business News
Print
PARIS--(BUSINESS WIRE)--EOS imaging  (Paris:EOSI)(Euronext, FR0011191766 – EOSI), the pioneer in orthopaedic 2D/3D imaging, announced today that the U.S. Food and Drug Administration has approved hipEOS, a 3D hip arthroplasty planning software based on EOS stereo-radiographic 2D/3D imaging. hipEOS is the first offering of a software portfolio associated with the EOS imaging system. Developed by OneFit medical, an EOS imaging group company, the software enables surgeons to perform, using EOS uni

imageimage
image

Read more